Evaluation Of Growth Based Bio Pharmaceutical Company Listed On The Financial Perspective

Biopharmaceutical industry is a sunrise industry in the21st century, but also the country over the past decade focused on supporting high-tech industries. From Biopharmaceuticals "85plan" to "Twelve Five-Year Plan", established a strategic position in the biopharmaceutical industry in China’s national economy, while residents of the demand for drugs and to expand economic capacity to pay for expensive drugs to improve these factors have contributed to the rapid development of China’s biopharmaceutical industry. But it appears the biopharmaceutical industry in the development process and product safety issues and other issues of low self-innovation capability, and is currently in the transition period, prices of raw materials, different levels of financial distress and shrinking exports caused by reduced financing became hinder unfavorable factors of the biopharmaceutical industry and stable growth. Therefore, the purpose of this paper is to identify affected by biopharmaceutical company growth factor, based on the financial perspective, the establishment of bio-pharmaceutical companies can effectively reflect the growth of the evaluation, and the total score is calculated by factor analysis, the results of objective evaluation and give corresponding recommendations to enhance the company’s growth.This article has the following five parts:The first chapter is the introduction, mainly on the research background, significance, research content and research methods, the main contribution. The second chapter of the literature review related to growth, based on the definition of the concept of growth on the development of growth factors combing theory, summarized and commented growth and evaluation. The third chapter and summarized the characteristics of the biopharmaceutical industry, and then analyzes the current situation of China’s bio-pharmaceutical industry by industrial output, sales value, R&D investment and other indicators, the final combination of the two cases summarized the impact of the growth of the biopharmaceutical industry factor. The fourth chapter mainly from the growth of quality, risk, speed, efficiency, innovation, social responsibility, operating cash flow of seven dimensions of eighteen financial indicators established biopharmaceutical evaluation of the company’s growth, and to select the appropriate methods and empirical this article model. Chose2010,89selected biopharmaceutical company listed on the Shanghai and Shenzhen stock markets to2010-2012data for the sample, with spss16.0statistical software and using factor analysis of the sample companies growth evaluation. Chapter fifth draw three conclusions:first, on the whole, the biopharmaceutical company listed on the poor performance of the overall growth of only6.74%of the samples the company’s growth performance is good; Second, from the geographical point of view, either the total sample or growth Comprehensive score eastern listed biopharmaceutical company growth relatively strong; Third, the growth momentum, the company’s profitability, cash operations, the contribution of the consumer, enterprise asset management conditions, the pace of development will be biopharmaceutical company growth for the total score has a greater impact. Finally, empirical results and development of bio-pharmaceutical company, given the proposed increase in the growth of biopharmaceutical companies: First, to strengthen the company’s own production management to produce high quality and high value-added biopharmaceuticals; secondly the ability to increase sales of products, to accelerate inventory turnover, making the company more cash flow faster input-output efficiency in the business operations; Finally, the cash flow used in biopharmaceutical research and development projects in the company’s core.